BWXT Medical Ltd. announced today that it has entered into a new long-term, mutually exclusive agreement to manufacture TheraSphere™ Y-90 Glass Microspheres for Boston Scientific, a leading global medical device company.
Developed for the treatment of patients with hepatocellular carcinoma (HCC), TheraSphere treatment is comprised of millions of glass microspheres containing radioactive Yttrium-90, which are delivered directly to liver tumors via a catheter, resulting in minimal exposure to surrounding healthy tissue.
Under the terms of the agreement, BWXT Medical will invest to automate the production process at its Ottawa, Canada facility, and thereby significantly increase capacity and dependability to support a growing global demand for TheraSphere.
To read more please visit:
Source: BWXT Technologies, Inc.